NIH-funded research R03 grant

Investigating the effects of memantine on cognitive function in individuals with Down syndrome

Official title: Down Syndrome Memantine Follow-up Study: EEG Data Analysis and Data Sharing with the Research Community

Funded at Case Western Reserve University · NIH-10876684 · Data updated 2026-11-12

This study is looking at how a higher dose of the drug memantine might help improve thinking and learning skills in young people with Down syndrome by analyzing brain activity data from a past trial.

Quick facts

Grant typeR03 grant
Study typeNIH-funded research
Funding institutionCase Western Reserve University
NIH-funded
Lab location1 site (Cleveland, United States)
Project startSeptember 20, 2024
Project endAugust 31, 2026
Funding year2024
Award (this year)$322,000
NIH project number1R03AG086928-01
Project IDNIH-10876684 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are adolescents and young adults aged 15-32 with Down syndrome who are in generally good health.

Less likely to help

Patients outside the age range of 15-32 or those with severe health complications may not benefit from this research.

What this research studies

This research focuses on analyzing EEG data from a previous trial that tested the drug memantine in adolescents and young adults with Down syndrome. The study aims to explore the potential cognitive benefits of higher doses of memantine, which may not have been evident in earlier trials. By sharing this data with the broader research community, the project hopes to enhance understanding of how memantine affects brain activity and cognitive function in this population. Participants will be monitored for any changes in cognitive and adaptive skills as a result of the treatment.

Why it matters

Potential benefit: If successful, this research could lead to improved treatment strategies for cognitive enhancement in individuals with Down syndrome.

How similar studies have gone: Previous studies have shown mixed results with memantine in similar populations, indicating that while this approach has been explored, the specific focus on higher doses in Down syndrome is relatively novel.

Where this research is happening

  • Case Western Reserve University
    Cleveland, United States
    Active

Researchers

  • Principal investigator: Costa, Alberto C S — Case Western Reserve University
  • Study coordinator: Costa, Alberto C S

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.